# US 2008/0187543 A1 · Use of Myostatin (Gdf-8) Antagonists for Improving Wound Healing and Preventing Fibrotic Disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0187543 A1
- Document ID: US20080187543A1
- Status: Published application
- Kind: A1
- Application number: 11/883,871
- Filed: 2006-02-07
- Published: 2008-08-07
- Earliest claimed: 2005-02-07
- Assignees: Orico Limited
- Inventors: Ravi Kambadur; Mridula Sharma; Alex Hennebry; Monica Senna Salerno de Moura
- Web page: https://patentgrep.com/patent/US20080187543A1

## CPC

- A61K 38/18: Growth factors; Growth regulators
- A61K 38/1808: {Epidermal growth factor [EGF] urogastrone}
- A61K 38/1858: {Platelet-derived growth factor [PDGF]}
- A61K 38/30: Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 {(insulin-like growth factor binding protein A61K38/1754)}
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 41/00: Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a method of improving wound healing in a human or animal patient by inhibiting the activity of myostatin (GDF-8) using one or more myostatin antagonists. The present invention also relates to a method of treating fibrotic diseases or disorders comprising administering a myostatin antagonist.

## Claims

### Claim 1

A method of improving tissue wound healing comprising the step of administering an effective amount of at least one myostatin antagonist to a human or non-human patient in need thereof.

### Claim 2 (depends on 1)

A method as claimed in claim 1, wherein the at least one myostatin antagonist is selected from the group consisting of:
an anti-myostatin antibody;
a myostatin peptide immunogen, myostatin multimer or myostatin immuno-conjugate capable of eliciting an immune response and blocking myostatin activity;
a protein inhibitor of myostatin selected from a truncated Activin type II receptor, a myostatin pro-domain and follistatin, or a functional fragment of said protein inhibitor;
a myostatin inhibitor released into culture from cells overexpressing myostatin;
a dominant negative of myostatin selected from the Piedmontese allele and mature myostatin peptides having a C-terminal truncation at a position at or between amino acid positions 335 to 375;
a small peptide comprising the amino acid sequence WMCPP and which is capable of binding to and inhibiting myostatin;
a splice variant of myostatin;
a regulator of the myostatin pathway; and
an antisense polynucleotide, RNAi, siRNA or an anti-myostatin ribozyme capable of inhibiting myostatin activity by inhibiting myostatin gene expression.

### Claim 3 (depends on 2)

A method as claimed in claim 2, wherein the at least one myostatin antagonist is a dominant negative of myostatin selected from the Piedmontese allele and mature myostatin peptides having a C-terminal truncation at a position at of between amino acid positions 335 to 375.

### Claim 4 (depends on 3)

A method as claimed in claim 3, wherein the at least one myostatin antagonist is a mature myostatin peptide having a C-terminal truncation at amino acid position 335 or 350.

### Claim 5 (depends on 2)

A method as claimed in claim 2, where the at least one myostatin antagonist is a splice variant of myostatin selected from a polypeptide of SEQ ID NOS: 8-14, or a functional fragment or variant thereof, or a sequence having 95%, 90%, 85%, 80%, 75% or 70% sequence identify thereto.

### Claim 6 (depends on 2)

A method as claimed in claim 2, wherein the at least one myostatin antagonist is a regulator of the myostatin pathway comprising the “mighty” peptide of SEQ ID NO: 16 or SEQ ID NO: 18, or a functional fragment or variant thereof, or a sequence having at least 95%, 90%, 85%, 80%, 75%, or 70% sequence identify thereto.

### Claim 7 (depends on 1)

A method as claimed in claim 1, for improving healing of a superficial skin wound, including cuts and abrasions; deep wound extending through the skin and muscle, including surgical incisions; internal wounds, including wounds to muscle and tendon caused by sports injury or trauma, bruises and hematomas; and burns.

### Claim 8 (depends on 1)

A method as claimed in claim 1, wherein one or more additional immuno-responsive compounds selected from the group consisting of glucocorticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), PDGF, EGF, IGF, and TNF-alpha antagonists are co-administered either separately, sequentially or simultaneously with the at least one myostatin antagonist to further improve wound healing.

### Claim 9 (depends on 1)

A method as claimed in claim 1, wherein the at least one myostatin antagonists is formulated for local or systemic administration.

### Claim 10 (depends on 9)

A method as claimed in claim 9, wherein the at least one myostatin antagonist is formulated for oral, intravenous, cutaneous, subcutaneous, intradermal, topical, nasal, pulmonary, intramuscular or intraperitional administration.

### Claim 11

A use of at least one myostatin antagonist in the manufacture of a medicament for improving tissue wound healing in a human or non-human patient in need thereof.

### Claim 12 (depends on 11)

A use as claimed in claim 11, wherein the at least one myostatin antagonist is selected from the group consisting of:
an anti-myostatin antibody;
a myostatin peptide immunogen, myostatin multimer or myostatin immuno-conjugate capable of eliciting an immune response and blocking myostatin activity;
a protein inhibitor of myostatin selected from a truncated Activin type II receptor, a myostatin pro-domain and follistatin, or a functional fragment of said protein inhibitor;
a myostatin inhibitor released into culture from cells overexpressing myostatin;
a dominant negative of myostatin selected from the Piedmontese allele and mature myostatin peptides having a C-terminal truncation at a position at or between amino acid positions 335 to 375;
a small peptide comprising the amino acid sequence WMCPP and which is capable of binding to and inhibiting myostatin;
a splice variant of myostatin;
a regulator of the myostatin pathway; and
an antisense polynucleotide, RNAi, siRNA or an anti-myostatin ribozyme capable of inhibiting myostatin activity by inhibiting myostatin gene expression.

### Claim 13 (depends on 12)

A use as claimed in claim 12, wherein the at least one myostatin antagonist is a dominant negative of myostatin selected from the Piedmontese allele and mature myostatin peptides having a C-terminal truncation at a position at of between amino acid positions 335 to 375.

### Claim 14 (depends on 13)

A use as claimed in claim 13, wherein the at least one myostatin antagonist is a mature myostatin peptide having a C-terminal truncation at amino acid position 335 or 350.

### Claim 15 (depends on 12)

A use as claimed in claim 12, where the at least one myostatin antagonist is a splice variant of myostatin selected from a polypeptide of SEQ ID NOS: 8-14, or a functional fragment or variant thereof, or a sequence having 95%, 90%, 85%, 80%, 75% or 70% sequence identify thereto.

### Claim 16 (depends on 12)

A use as claimed in claim 12, wherein the at least one myostatin antagonist is a regulator of the myostatin pathway comprising the “mighty” peptide of SEQ ID NO: 16 or SEQ ID NO: 18, or a functional fragment or variant thereof, or a sequence having at least 95%, 90%, 85%, 80%, 75%, or 70% sequence identify thereto.

### Claim 17 (depends on 11)

A use as claimed in claim 11, for improving healing of a superficial skin wound, including cuts and abrasions; deep wound extending through the skin and muscle, including surgical incisions; internal wounds, including wounds to muscle and tendon caused by sports injury or trauma, bruises and hematomas; and burns.

### Claim 18 (depends on 11)

A use as claimed in claim 11, wherein the medicament further comprises one or more additional immuno-responsive compounds selected from the group consisting of glucocorticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), PDGF, EGF, IGF, and TNF-alpha antagonists, and wherein the medicament is formulated for separate, sequential or simultaneous administration of the at least one myostatin antagonist and additional compound.

### Claim 19 (depends on 11)

A use as claimed in claim 11, wherein the medicament is formulated for local or systemic administration.

### Claim 20 (depends on 19)

A use as claimed in claim 19, wherein the medicament is formulated for oral, intravenous, cutaneous, subcutaneous, intradermal, topical, nasal, pulmonary, intramuscular or intraperitional administration.

### Claim 21

A pharmaceutical compound comprising at least one myostatin antagonist and a pharmaceutically acceptable carrier, when used in a method of improving wound healing in a human or non-human patient in need thereof.

### Claim 22 (depends on 21)

A pharmaceutical compound as claimed in claim 21, wherein the at least one myostatin antagonist is selected from the group consisting of:
an anti-myostatin antibody;
a myostatin peptide immunogen, myostatin multimer or myostatin immuno-conjugate capable of eliciting an immune response and blocking myostatin activity;
a protein inhibitor of myostatin selected from a truncated Activin type II receptor, a myostatin pro-domain and follistatin, or a functional fragment of said protein inhibitor;
a myostatin inhibitor released into culture from cells overexpressing myostatin;
a dominant negative of myostatin selected from the Piedmontese allele and mature myostatin peptides having a C-terminal truncation at a position at or between amino acid positions 335 to 375;
a small peptide comprising the amino acid sequence WMCPP and which is capable of binding to and inhibiting myostatin;
a splice variant of myostatin;
a regulator of the myostatin pathway; and
an antisense polynucleotide, RNAi, siRNA or an anti-myostatin ribozyme capable of inhibiting myostatin activity by inhibiting myostatin gene expression.

### Claim 23 (depends on 22)

A pharmaceutical compound as claimed in claim 22, wherein the at least one myostatin antagonist is a dominant negative of myostatin selected from the Piedmontese allele and mature myostatin peptides having a C-terminal truncation at a position at of between amino acid positions 335 to 375.

### Claim 24 (depends on 23)

A pharmaceutical compound as claimed in claim 23, wherein the at least one myostatin antagonist is a mature myostatin peptide having a C-terminal truncation at amino acid position 335 or 350.

### Claim 25 (depends on 22)

A pharmaceutical compound as claimed in claim 22, where the at least one myostatin antagonist is a splice variant of myostatin selected from a polypeptide of SEQ ID NOS: 8-14, or a functional fragment or variant thereof, or a sequence having 95%, 90%, 85%, 80%, 75% or 70% sequence identify thereto.

### Claim 26 (depends on 22)

A pharmaceutical compound as claimed in claim 22, wherein the at least one myostatin antagonist is a regulator of the myostatin pathway comprising the “mighty” peptide of SEQ ID NO: 16 or SEQ ID NO: 18, or a functional fragment or variant thereof, or a sequence having at least 95%, 90%, 85%, 80%, 75%, or 70% sequence identify thereto.

### Claim 27 (depends on 21)

A pharmaceutical compound as claimed in claim 21, for improving healing of a superficial skin wound, including cuts and abrasions; deep wound extending through the skin and muscle, including surgical incisions; internal wounds, including wounds to muscle and tendon caused by sports injury or trauma, bruises and hematomas; and burns.

### Claim 28 (depends on 21)

A pharmaceutical compound as claimed in claim 21, further comprising one or more additional immuno-responsive compounds selected from the group consisting of glucocorticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), PDGF, EGF, IGF, and TNF-alpha antagonists, wherein the composition is formulated for separate, sequential or simultaneous administration with the at least one myostatin antagonist.

### Claim 29 (depends on 21)

A pharmaceutical composition as claimed in claim 21, formulated for local or systemic administration.

### Claim 30 (depends on 29)

A pharmaceutical compound as claimed in claim 29, formulated for oral, intravenous, cutaneous, subcutaneous, intradermal, topical, nasal, pulmonary, intramuscular or intraperitional administration.

### Claim 31

At least one myostatin antagonist when used in a method of improving wound healing in a human or non-human patient in need thereof.

### Claim 32 (depends on 31)

At least one myostatin antagonist as claimed in claim 31, is selected from the group consisting of:
an anti-myostatin antibody;
a myostatin peptide immunogen, myostatin multimer or myostatin immuno-conjugate capable of eliciting an immune response and blocking myostatin activity;
a protein inhibitor of myostatin selected from a truncated Activin type II receptor, a myostatin pro-domain and follistatin, or a functional fragment of said protein inhibitor;
a myostatin inhibitor released into culture from cells overexpressing myostatin;
a dominant negative of myostatin selected from the Piedmontese allele and mature myostatin peptides having a C-terminal truncation at a position at or between amino acid positions 335 to 375;
a small peptide comprising the amino acid sequence WMCPP and which is capable of binding to and inhibiting myostatin;
a splice variant of myostatin;
a regulator of the myostatin pathway; and
an antisense polynucleotide, RNAi, siRNA or an anti-myostatin ribozyme capable of inhibiting myostatin activity by inhibiting myostatin gene expression.

### Claim 33 (depends on 32)

At least one myostatin antagonist as claimed in claim 32, comprising a dominant negative of myostatin selected from the Piedmontese allele and mature myostatin peptides having a C-terminal truncation at a position at of between amino acid positions 335 to 375.

### Claim 34 (depends on 33)

At least one myostatin antagonist as claimed in claim 33, comprising a mature myostatin peptide having a C-terminal truncation at amino acid position 335 or 350.

### Claim 35 (depends on 32)

At least one myostatin antagonist as claimed in claim 32, comprising a splice variant of myostatin selected from a polypeptide of SEQ ID NOS: 8-14, or a functional fragment or variant thereof, or a sequence having 95%, 90%, 85%, 80%, 75% or 70% sequence identify thereto.

### Claim 36 (depends on 32)

At least one myostatin antagonist as claimed in claim 32 comprising a regulator of the myostatin pathway comprising the “mighty” peptide of SEQ ID NO: 16 or SEQ ID NO: 18, or a functional fragment or variant thereof, or a sequence having at least 95%, 90%, 85%, 80%, 75%, or 70% sequence identify thereto.

### Claim 37 (depends on 31)

At least one myostatin antagonist as claimed in claim 31 for improving healing of a superficial skin wound, including cuts and abrasions; deep wound extending through the skin and muscle, including surgical incisions; internal wounds, including wounds to muscle and tendon caused by sports injury or trauma, bruises and hematomas; and burns.

### Claim 38 (depends on 31)

At least one myostatin antagonist as claimed in claim 31 in combination with one or more additional immuno-responsive compounds selected from the group consisting of glucocorticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), PDGF, EGF, IGF, and TNF-alpha antagonists for separate, sequential or simultaneous administration with the at least one myostatin antagonist to further improve wound healing.

### Claim 39 (depends on 31)

At least one myostatin antagonists as claimed in claim 31, formulated for local or systemic administration.

### Claim 40 (depends on 39)

At least one myostatin antagonist as claimed in claim 39 formulated for oral, intravenous, cutaneous, subcutaneous, intradermal, topical, nasal, pulmonary, intramuscular or intraperitional administration.

### Claim 41

A method of treating fibrotic diseases or disorders comprising administering to a patient in need thereof a therapeutically effective amount of a myostatin antagonist.
